COVAX - Time to reconsider the strategy and its target.
Health Policy Open
; 4: 100096, 2023 Dec.
Article
in English
| MEDLINE | ID: covidwho-2292106
ABSTRACT
COVAX, the international initiative supporting COVID-19 vaccination campaigns globally, is budgeted to be the costliest public health initiative in low- and middle-income countries, with over 16 billion US dollars already committed. While some claim that the target of vaccinating 70% of people worldwide is justified on equity grounds, we argue that this rationale is wrong for two reasons. First, mass COVID-19 vaccination campaigns do not meet standard public health requirements for clear expected benefit, based on costs, disease burden and intervention effectiveness. Second, it constitutes a diversion of resources from more cost-effective and impactful public health programmes, thus reducing health equity. We conclude that the COVAX initiative warrants urgent review.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Topics:
Vaccines
Language:
English
Journal:
Health Policy Open
Year:
2023
Document Type:
Article
Affiliation country:
J.hpopen.2023.100096
Similar
MEDLINE
...
LILACS
LIS